London, UK – July 15, 2026 – The Alzheimer’s Association International Conference (AAIC) 2026, held in London this past week, served as a critical juncture for the global research community, offering a comprehensive overview of recent breakthroughs while starkly illuminating the persistent hurdles in the fight against Alzheimer’s disease. While the advent of disease-modifying therapies (DMTs) and the growing accessibility of blood-based biomarkers represent significant advancements, discussions at the conference underscored the urgent need for greater therapeutic availability, optimized treatment strategies, and equitable access to diagnostic tools.
The AAIC 2026, spanning July 12-15, brought together leading scientists, clinicians, and industry representatives to dissect the evolving treatment landscape. The overarching sentiment was one of cautious optimism, tempered by the recognition that transformative progress in drug development and diagnostics is only the first step in a complex journey towards effective and accessible Alzheimer’s care. Key themes that dominated the congress included the burgeoning understanding of Alzheimer’s subtypes, the critical role and limitations of biomarkers, the imperative of diversity in research, and the optimization of treatment paradigms.
The Dawn of New Therapies and Biomarker Diagnostics
In recent years, the field of Alzheimer’s research has witnessed unprecedented progress. The regulatory approval of the first disease-modifying therapies (DMTs) and the development of blood-based biomarker tests have opened new avenues for both diagnosis and treatment. These innovations hold the potential to revolutionize how Alzheimer’s is managed, shifting the focus from symptomatic relief to targeting the underlying pathology of the disease.
The AAIC 2026 provided a platform for experts to delve into these developments, examining their impact on research and development (R&D), clinical practice, and patient care. While celebrating these milestones, the conference also served as a vital forum for reflection, identifying areas where further innovation and strategic planning are essential to overcome existing gaps and ensure that these advancements translate into tangible benefits for all affected individuals.
Unraveling the Complexities: Alzheimer’s Subtypes and the Future of R&D
The Shifting Paradigm: From Single Disease to Heterogeneous Condition
For over a century, Alzheimer’s disease was largely conceptualized as a singular entity. However, emerging research presented at AAIC 2026 strongly suggests that this monolithic view is no longer tenable. The intricate nature of the disease, characterized by significant variations in symptom presentation, progression rates, and long-term outcomes among patients, has propelled the exploration of Alzheimer’s as a collection of distinct subtypes.
Groundbreaking Research on Alzheimer’s Subtypes
A pivotal presentation by Dr. Betty Tijms, an associate professor at the Alzheimer Center in Amsterdam, challenged the conventional understanding of Alzheimer’s as a single disease. Through comprehensive proteomic and metabolomic analyses of cerebrospinal fluid (CSF) samples, Dr. Tijms proposed the existence of at least five distinct subtypes of Alzheimer’s. These subtypes are believed to be driven by different underlying biological mechanisms, including neuronal hyperplasticity, innate immune responses, and blood-brain barrier impairment.
Dr. Tijms theorized that the heterogeneity of Alzheimer’s subtypes could explain the failure of certain therapies in clinical trials, as these treatments may not have been administered to the specific patient populations most likely to benefit. The identification of these subtypes, she posited, could also illuminate novel therapeutic targets beyond the traditional amyloid and tau pathways, offering drug developers new avenues for exploration.
Implications for Drug Development and Diagnosis
The potential validation of Dr. Tijms’ theory carries profound implications for Alzheimer’s drug development. It underscores the necessity for subtype-specific biomarkers and therapeutics, and highlights the critical role of CSF-based proteomics in achieving accurate diagnosis and personalized treatment.
Samuel Dickson, SVP of statistics at biostatistics consultancy firm Pentara, acknowledged the growing trend among sponsors to tailor development efforts to specific subtypes, though he noted this is contingent on the explored mechanism of action. "Heterogeneity is a fact of life," Dickson stated. "You have to have pretty clear delineation to say ‘we’re going to rule out this entire subpopulation’ because you’ll be dealing with larger screen fail rates and costs. So, the benefit to a trial has to be clear if you’re going to deal with the heterogeneity."
Francesca Capotosti, SVP of research at AC Immune, a company developing a range of Alzheimer’s drugs targeting pathways including pathological tau, neuroinflammation, and misfolded amyloid-beta, concurred with Dickson’s sentiment. She believes that patient subclassification is the future direction of the field, although the research is still in its nascent stages, limiting widespread implementation.
Biomarkers Take Center Stage, But Imaging Accessibility Remains a Concern
The Rise of Blood-Based Biomarkers
The 2026 Alzheimer’s Association International Conference (AAIC) was abuzz with discussions surrounding the burgeoning role of biomarkers, particularly blood-based tests. Tests for key disease indicators, such as phosphorylated tau protein (p-tau217), are increasingly being heralded as the next frontier in accessible Alzheimer’s research and care.
Christopher Weber, director of global science initiatives at the Alzheimer’s Association, previously emphasized to Clinical Trials Arena that non-invasive screening methods, including digital biomarkers and blood tests, could bridge the gap between primary and specialist neurological care. This is particularly crucial given the persistent undersupply of memory specialists and the primary role of general practitioners as the initial point of contact for patients.
Socioeconomic Barriers to Diagnostic Access
Despite the promise of biomarkers, researchers focused on the socioeconomic aspects of Alzheimer’s disease voiced significant concerns regarding the accessibility of diagnostic tools. While blood-based biomarkers are generally considered more affordable and accessible than imaging techniques like MRI or amyloid PET scans, access remains a significant challenge in many regions.
During a session on the real-world implementation of anti-amyloid therapies, Brazilian neurologist Elisa de Paula França Resende highlighted the severe limitations in access to CSF and plasma biomarker tests in Latin America. The absence of public coverage in these regions necessitates out-of-pocket payments for patients, creating a substantial financial barrier.
The Need for Robust Global Healthcare Infrastructure
Resende, along with Jonathan Schott, professor of neurology at University College London (UCL), agreed that global healthcare systems are not yet adequately prepared to meet the demand for these diagnostic tools. Professor Schott noted in his presentation that testing infrastructure across Europe requires significant bolstering to accommodate the rising demand for early imaging and ongoing monitoring associated with anti-amyloid therapies.
Suchandrima Banerjee, general manager of neurology care pathways at GE Healthcare, acknowledged the recent debut of novel biomarkers for the screening and triage process. She emphasized their complementary role alongside MRI and PET-based methods, stating, "We see these approaches as complementary because Alzheimer’s is a population-level disease."
Banerjee advocated for the development of a diverse range of screening and triaging tools to assist healthcare systems in identifying patients likely to have Alzheimer’s. This, she explained, would facilitate more targeted confirmatory diagnoses through tools like amyloid PET. GE Healthcare is actively developing digital tools to optimize imaging processes and provides advanced imaging machinery, including MRI, PET/MR, and PET/CT scanners, for screening purposes.
The Imperative of Diversity for Enhanced R&D and Patient Outcomes
Diversity as a Non-Negotiable in Clinical Trials
A central and urgent theme at AAIC 2026 was the critical need for equitable inclusion in Alzheimer’s research. Experts issued stark warnings that the persistent lack of diversity within clinical trials poses a significant threat to the ethical integrity, scientific validity, and real-world applicability of both clinical and post-marketing studies.
A dedicated panel discussion unequivocally declared diversity and inclusion in trials as an absolute necessity, not merely an optional consideration. To achieve this, researchers advocated for a community-centric approach, actively involving patients in the co-development process and meticulously considering specific cultural needs during the research design phase.
Industry Initiatives for Inclusive Research
Klaus Dugi, CEO of biotech firm Vandria, which is developing an Alzheimer’s drug, VNA-318, outlined his company’s proactive approach to enhancing diversity. Vandria is conducting a smaller, yet broader, trial to assess patient characteristics, biomarkers, and cognitive parameters, aiming to identify specific subpopulations that may derive greater benefit from the therapy. "In the first study, we don’t want to restrict the patient population too much – we want to learn if there’s a group that may accrue a particularly high benefit, such as patients with two copies of the APOE4 gene, as we have preclinical data suggesting that they may benefit especially," Dugi explained.
Neil Warma, CEO of ProMIS Neurosciences, a company developing an Alzheimer’s therapy targeting toxic amyloid oligomers, believes that artificial intelligence (AI) for trial design and computational models for real-world evidence (RWE) generation will be instrumental in advancing accessibility and diversity within the field.
Optimizing Treatment Strategies for Improved Patient Outcomes
The Era of Combination Therapies
As disease-modifying anti-amyloid therapies such as Biogen and Eisai’s Leqembi (lecanemab) and Eli Lilly’s Kisunla (donanemab) become increasingly integrated into the Alzheimer’s treatment paradigm, pharmaceutical companies and researchers are actively exploring avenues to further enhance patient outcomes. This pursuit involves both the development of novel medications and the optimization of the utilization of existing tools.
A widely discussed strategy at AAIC 2026 was the adoption of combination therapeutic approaches. This sentiment was echoed by Dugi, Warma, and Capotosti, who advocated for the pairing of anti-amyloid drugs with different mechanisms of action, as well as their combination with tau-targeting therapies, such as Biogen’s diranersen, and modulators of neuroinflammation. Several presenters at the conference, including Dugi and Capotosti, highlighted the significant potential of mitigating neuroinflammation as a key treatment strategy for Alzheimer’s.
Early Intervention and Prophylactic Therapies
Pharmaceutical companies are also investigating the application of anti-amyloid treatments in earlier stages of the disease. Roche announced at AAIC 2026 the initiation of a Phase III study, PrevenTRON, for its late-stage amyloid-targeting Alzheimer’s hopeful, trontinemab. This move is driven by research suggesting that the removal of amyloid plaques in the preclinical stages of Alzheimer’s, before the onset of noticeable cognitive decline, could lead to improved care and long-term patient benefits.
The Cruciality of Early Diagnosis
Despite these promising advancements, experts at AAIC 2026 reiterated the paramount importance of early diagnosis. They emphasized that timely diagnosis is essential to unlock the full therapeutic benefits of emerging treatments, particularly as current therapeutic options are primarily designed for individuals in the early stages of Alzheimer’s disease. The ongoing dialogue at the conference underscored that while the scientific landscape is rapidly evolving, the journey towards a comprehensive and equitable solution for Alzheimer’s disease is far from over. The insights gained at AAIC 2026 will undoubtedly shape the trajectory of research and care for years to come, reinforcing the need for continued collaboration, innovation, and a steadfast commitment to addressing the multifaceted challenges posed by this devastating disease.
About the Author
